Longitudinal evaluation of the complexed-to-total prostate specific antigen ratio in men with prostate disease. Effect of treatment

European Journal of Cancer

Volumn 34, Issue 9, 1998, Pages 1375-1380

  Espana F ^a   Martinez M ^a   Royo, M ^a   Vera, C D ^a   Estelles A ^a   Aznar, J ^a   Jimenez Cruz J F ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

1 antichymotrypsin; Benign prostate hyperplasia; Complexed PSA; Prostate cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RECURRENCE; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; TREATMENT OUTCOME;

ALPHA 1-ANTICHYMOTRYPSIN; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; LONGITUDINAL STUDIES; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SERINE PROTEINASE INHIBITORS;

EID: 0032146729     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00078-1     Document Type: Article

References (29)

1. 1. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 317, 909-916.
2. 2. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991, 324, 1156-1161.
3. 3. Drago JR, Badalament RA, Wientjes MG, et al. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience. Urology 1989, 34, 187-193.
4. 4. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991, 145, 907-923.
5. 5. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989, 141, 873-879.
6. 1-antichymotrypsin. Clin Chem 1991, 37, 1618-1625.
7. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991, 51, 222-226.
8. 2-macroglobulin complexes in prostate cancer patient sera. Biochem Mol Biol Int 1995, 37, 917-923.
9. 2-macroglobulin. Clin Chem 1996, 42, 545-550.
10. 1-antichymotrypsin complexes in serum. Eur J Clin Chem Clin Biochem 1991, 29, 787-794.
11. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993, 150, 100-105.
12. 1-antichymotrypsin: influence of cancer volume, location and therapeutic selection of resistant clones. J Urol 1994, 152, 1510-1514.
13. 1-antichymotrypsin in the plasma of patents with prostatic disease. Eur Urol 1996, 30, 512-518.
14. 14. Wu JT, Wilson L, Zhang P, Meikle AW, Stephenson R. Correlation of serum concentrations of PSA:ACT complex with total PSA in random and serial specimens from patients with BPH and prostate cancer. J Clin Lab Anal 1995, 9, 15-24.
15. 15. Stenman U-H, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha(1)-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994, 344, 1594-1598.
16. 16. Takayama TK, Vessella RL, Lange PH. Newer applications of serum prostate-specific antigen in the management of prostate cancer. Semin Oncol 1994, 21, 542-553.
17. 17. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995, 274, 1214-1220.
18. 18. Prestigiacomo AF, Stamey TA. Clinical usefulness of free and complexed PSA. Scand J Clin Lab Invest 1995, 55, 32-34.
19. 19. Filella X, Alcover J, Molina R, Rodríguez A, Carretero P, Ballesta AM. Clinical evaluation of free PSA/total PSA (prostate-specific antigen) ratio in the diagnosis of prostate cancer. Eur J Cancer 1997, 33, 1226-1229.
20. 20. España F, Martínez M, Royo M, et al. Reference ranges for the concentrations of total and complexed plasma prostate-specific antigen and their ratio in patients with benign prostate hyperplasia. Eur Urol 1997, 32, 268-272.
21. 21. Oesterling JE, Jacobsen SJ, Klee GG, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995, 154, 1090-1095.
22. 22. Sensabaugh GF, Blake ET. Seminal plasma protein p30: simplified purification and evidence for identity with prostate-specific antigen. J Urol 1990, 144, 1523-1526.
23. 23. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its interaction with extracellular serine proteinase inhibitors. Eur J Biochem 1990, 194, 755-763.
24. 24. Huber PR, Schmid HP, Mattarelli G, Strittmatter B, Steenbrugge GJ van. Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate. Prostate 1995, 27, 212-219.
25. 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 1994, 43, 427-434.
26. 26. Kabalin JN, McNeal JE, Price HM, Freiha FS, Stamey TA. Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J Urol 1989, 151, 1091-1096.
27. 27. Christensen WN, Partin AW, Walsh PC, Epstein JI. Pathologic findings in clinical stage A2 prostate cancer: relation of tumor volume, grade, and location to pathologic state. Cancer 1990, 65, 1021-1025.
28. 28. Greene DR, Wheeler TM, Egawa S, Dunn JK, Scardino PT. A comparison of the morphological features of cancer arising in the transition zone in the peripheral zone of the prostate. J Urol 1991, 146, 1069-1076.
29. 29. Bjartell A, Björk T, Matikainen MT, Abrahamsson PA, di Sant'Agnese A, Lilja H. Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium. Urology 1993, 42, 502-510.